NO20060081L - Pyrrol-2,5-dionderivater som lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-dionderivater som lever X reseptormodulatorer

Info

Publication number
NO20060081L
NO20060081L NO20060081A NO20060081A NO20060081L NO 20060081 L NO20060081 L NO 20060081L NO 20060081 A NO20060081 A NO 20060081A NO 20060081 A NO20060081 A NO 20060081A NO 20060081 L NO20060081 L NO 20060081L
Authority
NO
Norway
Prior art keywords
pyrrole
supplying
receptor modulators
dione derivatives
methods
Prior art date
Application number
NO20060081A
Other languages
English (en)
Norwegian (no)
Inventor
Christer Westerlund
Pernilla Marie Sandberg
Kay Brickmann
Patrik Holm
Jonas Bostrom
Marianne Swanson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060081L publication Critical patent/NO20060081L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20060081A 2003-07-11 2006-01-05 Pyrrol-2,5-dionderivater som lever X reseptormodulatorer NO20060081L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20060081L true NO20060081L (no) 2006-02-08

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060081A NO20060081L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-dionderivater som lever X reseptormodulatorer

Country Status (25)

Country Link
US (1) US7432288B2 (https=)
EP (1) EP1646626B1 (https=)
JP (1) JP2007521312A (https=)
KR (1) KR20060035748A (https=)
CN (1) CN1823061A (https=)
AR (1) AR045721A1 (https=)
AT (1) ATE399777T1 (https=)
AU (1) AU2004255999B2 (https=)
BR (1) BRPI0412472A (https=)
CA (1) CA2532056A1 (https=)
DE (1) DE602004014773D1 (https=)
ES (1) ES2308204T3 (https=)
GB (1) GB0316232D0 (https=)
IL (1) IL172760A0 (https=)
IS (1) IS8293A (https=)
MX (1) MXPA06000414A (https=)
MY (1) MY135821A (https=)
NO (1) NO20060081L (https=)
RU (1) RU2006102130A (https=)
SA (1) SA04250204B1 (https=)
TW (1) TW200503691A (https=)
UA (1) UA82109C2 (https=)
UY (1) UY28408A1 (https=)
WO (1) WO2005005417A1 (https=)
ZA (1) ZA200600222B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
WO2007128458A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
JP2013544837A (ja) 2010-12-03 2013-12-19 アラーガン インコーポレイテッド スフィンゴシン−1−リン酸(s1p)受容体モジュレーターとしての新規オキシムアゼチジン誘導体
AU2011336970A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク インコーポレイテッド Hdlコレステロール値を上昇させる組成物および方法
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
CA2532056A1 (en) 2005-01-20
IS8293A (is) 2006-02-09
BRPI0412472A (pt) 2006-09-19
US20060235015A1 (en) 2006-10-19
TW200503691A (en) 2005-02-01
AU2004255999A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
JP2007521312A (ja) 2007-08-02
ATE399777T1 (de) 2008-07-15
KR20060035748A (ko) 2006-04-26
US7432288B2 (en) 2008-10-07
MY135821A (en) 2008-07-31
UA82109C2 (uk) 2008-03-11
WO2005005417A1 (en) 2005-01-20
IL172760A0 (en) 2006-04-10
AR045721A1 (es) 2005-11-09
CN1823061A (zh) 2006-08-23
GB0316232D0 (en) 2003-08-13
ES2308204T3 (es) 2008-12-01
SA04250204B1 (ar) 2008-03-23
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
EP1646626B1 (en) 2008-07-02
RU2006102130A (ru) 2007-08-20
UY28408A1 (es) 2005-02-28
EP1646626A1 (en) 2006-04-19
DE602004014773D1 (de) 2008-08-14
MXPA06000414A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
NO20055892L (no) Karboksylsyrederivater
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2006022428A1 (ja) 糖尿病治療剤
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
WO2007092416A3 (en) Melanin concentrating hormone receptor-1 antagonists
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
ATE496622T1 (de) Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten
NO20060612L (no) Spiro [1-azabicyklo[2.2.2]-oktan-3,5'-oksazolidin]-2'-on-derivater med affinitet til alfa-7-nikotin-acetylcholin reseptoren
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
NO20063329L (no) Tricykliske steroidhormone nukleaer reseptormodulatorer
CN103040779A (zh) 用于神经系统疾病的口服固体药物组合物
JP2008526953A (ja) 炎症性疾患のプラジカンテルでの治療
NO20065501L (no) Lxr reseptor modulstorer.
JP7841019B2 (ja) ナツメ属植物及びガラナの生物活性植物化学物質
TWI676624B (zh) 新穎化合物
SE0500056D0 (sv) Therapeutic agents 4
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
CN101663035A (zh) 4-环丙基甲氧基-n-(3,5-二氯代-1-环氧-吡啶-4-基)-5-(甲氧基)吡啶-2-甲酰胺用于治疗与帕金森症有关的运动障碍的用途

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application